[ Visit Client Website ]

Before you can access ASH's online program, you must agree to the following:
  • Abstracts submitted to the ASH Annual Meeting are considered embargoed from the time of submission.
  • The media, companies and institutions issuing press releases, and others are required to abide by the embargo policies governing the Society’s annual meeting. Read ASH’s embargo policy for more information.
Last updated December 3, 2009. Please note that this site represents the latest program changes
and differs from the print version in some details.

653A.O3.6 Myeloma - Therapy, excluding Transplantation II

Oral and Poster Abstracts
Oral Session
Monday, December 7, 2009: 2:45 PM-4:15 PM
La Nouvelle Ballroom AB (Ernest N. Morial Convention Center)
Moderators:
Antonio Palumbo and Brian G M Durie
2:45 PM
A Phase III Study to Determine the Efficacy and Safety of Lenalidomide in Combination with Melphalan and Prednisone (MPR) in Elderly Patients with Newly Diagnosed Multiple Myeloma

Antonio Palumbo1, Meletios A. Dimopoulos2, Michel Delforge3, Martin Kropff4, Robin Foa5*, Zhinuan Yu6*, Lindsay Herbein6*, Jay Mei6*, Christian Jacques6* and John Catalano7

1Division of Hematology, University of Torino, Torino, Italy
2Department of Clinical Therapeutics, Alexandra Hospital, University of Athens School of Medicine, Athens, Greece
3University Hospital Leuven, Leuven, Belgium
4Department of Medicine (Hematology/Oncology), University of Muenster, Muenster, Germany
5Division of Hematology, University, Rome, Italy
6Celgene Corporation, Summit, NJ
7Haematology Dept and Dorevitch Pathology, Frankston Hospital, Frankston, Australia

3:00 PM
Multicenter, Randomized, Open-Label, Phase III Trial of Lenalidomide-Dexamethasone (Len/dex) Vs Therapeutic Abstention in Smoldering Multiple Myeloma at High Risk of Progression to Symptomatic MM: Results of the First Interim Analysis

Maria-Victoria Mateos, MD, PhD1*, Lucía López-Corral2*, Miguel T Hernández3*, Javier de la Rubia4*, Juan José Lahuerta, MD, PhD5*, Pilar Giraldo, MD6, Joan Bargay, MD7*, Laura Rosiñol8*, Albert Oriol, MD9*, Jose García-Laraña10*, Luis Palomera11*, Felipe de Arriba12*, Felipe Prosper, MD13, Mariluz Martino, MD14*, Ana-Isabel Teruel15*, José Hernández16*, Graça Esteves17*, Mario Mariz18*, Adrian Alegre, MD19*, J.L. Guzmán20*, Nuria Quintana21*, Jose-Luis Garcia21* and Jesús F. San-Miguel, MD, PhD22

1Haematology, Hospital Universitario de Salamanca, Salamanca, Spain
2Centro de Investigación del Cáncer. IBMCC/CSIC, University of Salamanca, Salamanca, Spain
3Hospital Universitario de Canarias, Tenerife, Spain
4Hospital La Fe, Valencia, Spain
5Hospital 12 de Octubre, Madrid, Spain
6Hospital Miguel Servet, Zaragoza, Spain
7Hematology, Hospital Son Llatzer, Palma de Mallorca, Spain
8Hospital Clinic i Provincial, Barcelona, Spain
9Hospital Universitari Germans Trias i Pujol, Badalona, Spain
10Hemaology, Hospital Ramón y Cajal, Madrid, Spain
11Hospital Lozano Blesa, Zaragoza, Spain
12Hematology, Hospital Morales Meseguer, Murcia, Spain
13Hematology & Cell Therapy Prog., Clinica Universitaria de Navarra, Pamplona, Spain
14Hematology and Hemotherapy Department, Hospital Universitario Virgen del Rocío, Seville, Spain, Spain
15Hematology, Hospital Clinico Universitario de Valencia, Valencia, Spain
16Hospital General de Segovia, Segovia, Spain
17Hematologia e Transplante de Medula Ossea, Hospital de Santa Maria, Lisbon, Portugal
18Hematology, Instituto Portugues Oncologia Porto, Porto
19Hospital de La Princesa, Madrid, Spain
20Hematology, Hospital del SAS de Jerez de la Frontera, Jerez de la Frontera, Spain
21Celgene Corporation, Madrid, Spain
22Po. San Vicente, 58-182, Hospital Clinico Universitario de Salamanca, Salamanca, Spain

3:15 PM
Melphalan and Prednisone (MP) Versus Melphalan, Prednisone and Thalidomide (MPT) as Initial Therapy for Previously Untreated Elderly and/or Transplant Ineligible Patients with Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials

Prashant Kapoor, MD1*, S. Vincent Rajkumar, MD1*, Angela Dispenzieri, MD1*, Martha Q. Lacy, MD1*, David Dingli, M.D., PhD.1, Robert Kyle, M.D.1, Morie A. Gertz, MD1*, Philip . R Greipp, MD1*, Shaji Kumar, MD1 and Sumithra J. Mandrekar, PhD2*

1Hematology, Mayo Clinic, Rochester, MN
2Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN

3:30 PM
A Phase II Trial Comparison of Once Versus Twice Weekly Bortezomib in CYBORD Chemotherapy for Newly Diagnosed Myeloma: Identical High Response Rates and Less Toxicity

Craig B. Reeder, MD1, Donna E. Reece2, Vishal Kukreti, MD, FRCPC3, Joseph R. Mikhael, MD1, Christine Chen, MD3, Suzanne Trudel, MD3*, Kristina Laumann4*, Joseph Hentz1*, Nick Pirooz1*, Jg Piza, MD3*, Victor J Jimenez Zepeda1*, Rafael Fonseca1*, P. Leif Bergsagel1*, Jose Leis1*, Rodger E. Tiedemann, MBChB, PhD, FRACP, FRCPA1 and A. Keith Stewart, MBChB1

1Mayo Clinic Arizona, Scottsdale, AZ
2Princess Margaret Hospital, University Health Network, Toronto, ON, Canada
3Princess Margaret Hospital, Toronto, ON, Canada
4Mayo Clinic, Rochester, MN

3:45 PM
Phase I Study of Bortezomib(Bz), Pegylated Doxorubicin(DOX) and Dexamethasone(dex); ( VDD) with Escalating Doses of Cyclophosphamide(Cy) in Patients with Newly Diagnosed Myeloma

Melissa Alsina, MD1, Rachid Baz, MD2, Jose L Ochoa, MD1*, Jyotishankar Raychaudhuri1*, Kara Kosakowski2*, Michelle Mintz3*, Kendra Anderson3*, William S Dalton, M.D., Ph.D4* and Daniel Sullivan1

1Bone Marrow Transplant Program, H. Lee Moffitt Cancer Center, Tampa, FL
2Malignant Hematology Program, H. Lee Moffitt Cancer Center, Tampa, FL
3Phase I Program, Moffitt Cancer Center, Tampa, FL
4Hematology Oncology and Experimental Therapeutics, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL

4:00 PM
Bortezomib in Combination with Pegylated Liposomal Doxorubicin and Thalidomide (VDT), An Effective Steroid Independent Regimen for Previously Untreated Multiple Myeloma Patients: Final Result of a Phase II Study

Taimur Sher, MD1*, Kena C Miller1*, Sikander Ailawadhi, MD2, Debbie Manfredi1*, Margaret Wood1*, Wei Tan, Ph.D.3*, Gregory Wilding, Ph.D.3*, Hong Liu, MD1*, Myron S Czuczman, MD1, Francisco Hernandez, MD1*, Frederick Hong, MD4*, Raman Sood, MD5*, Saif Soniwalla, MD4*, William Lawrence, MD4, Peter A. Kouides, MD6, Kelvin P. Lee, MD7 and Asher Chanan-Khan, MD1

1Medicine, Roswell Park Cancer Institute, Buffalo, NY
2Jane Anne Nohl Division of Hematology, University of Southern California, Los Angeles, CA
3Biostatistics, Roswell Park Cancer Institute, Buffalo, NY
4Roswell Park Community Network, Williamsville, NY
5Roswell Park Community Network, Dunkirk, NY
6Roswell Park Community Network, Rochester, NY
7Immunology, Roswell Park Cancer Institute, Buffalo, NY

*signifies non-member of ASH